Manitou Investment Management Ltd. significantly increased its stake in Roper Technologies (NASDAQ: ROP) by 8.8% in the fourth quarter, now holding 80,166 shares valued at approximately $35.7 million. This move highlights the continued high institutional ownership of Roper, with hedge funds and other institutional investors collectively owning 93.31% of the company's shares. Despite varied analyst ratings, with a consensus "Hold" and an average price target of $472.07, the company recently reported strong quarterly earnings, surpassing analyst estimates, and announced a quarterly dividend.

Hershey Trust Co. significantly reduced its stake in The Hershey Company by 96.4% in Q4, but still holds 2.07 million shares valued at approximately $376 million, making it their second-largest holding. The Hershey Company reported strong quarterly results, exceeding EPS and revenue estimates, and announced a quarterly dividend of $1.452 per share. Despite these positive financial indicators, analysts generally maintain a "Hold" rating on the stock with a consensus target price of $218.06.

Columbus McKinnon Corporation reported mixed fourth-quarter results, with an earnings per share miss of $0.24 against an expected $0.47, but a revenue beat at $437.8 million, significantly exceeding estimates. The revenue surge was mainly attributed to the Kito Crosby acquisition. The company provided fiscal 2027 guidance forecasting EPS aligning with analyst expectations and revenue slightly above consensus.

MarketAxess Holdings Inc. (MKTX) announced its May 2026 trading volumes, showing an increase in U.S. high-grade estimated market share to 17.8% and total credit average daily volume growing 4% year-over-year. Despite these gains, MKTX shares are near their 52-week low, trading at $122.98 against an InvestingPro Fair Value of $188.58, indicating it may be significantly undervalued. The company also reported strong Q1 2026 financial results, exceeding EPS and revenue expectations.

Greenspring Advisors LLC significantly increased its stake in Costco Wholesale Corporation by 198.7% in the fourth quarter, bringing its total holdings to 2,318 shares valued at approximately $2.0 million. This comesamid continued strong institutional ownership, with other major investors like Vanguard and Geode Capital also maintaining large positions. Despite the stock trading at a premium valuation and a slight EPS miss in its last earnings report, analysts remain bullish, with TD Cowen reaffirming a "Buy" rating and raising its price target to $1,175 following strong May sales growth.

Verizon Communications' Executive VP & Chief Human Resources Officer, Samantha Hammock, recently sold US$3.5m worth of company stock, representing 82% of her holding. This transaction and the lack of insider buying over the past year raise caution for potential investors. While insider ownership is modest at 0.03%, the analysis suggests watchful consideration before investing in VZ.

Insulet Corporation announced its plans for the American Diabetes Association's 86th Scientific Sessions, where it will showcase new data and innovations for its Omnipod® tubeless insulin pump technology. The company will highlight advancements in its Omnipod 5 algorithm, including a lower Target Glucose setting and integration with Abbott’s FreeStyle Libre 3 Plus sensor, alongside results from pivotal trials like STRIVE and EVOLUTION 3. Insulet aims to demonstrate how its patient-centered design and strong clinical performance are redefining Automated Insulin Delivery for both type 1 and type 2 diabetes.

Regeneron (NASDAQ: REGN) is set to present new clinical and preclinical data at the ADA (June 5-8) and ENDO (June 13-16) 2026 conferences. Key presentations will include Phase 2 COURAGE trial data on trevogrumab for obesity and muscle biology, Phase 3 OPTIMA FOP results for garetosmab for the ultra-rare bone disorder fibrodysplasia ossificans progressiva, and early research on an antibody for Graves' and thyroid eye disease. These presentations underscore Regeneron's efforts in addressing significant unmet medical needs across metabolic, ophthalmology, and rare disease pipelines.

Jefferies has upgraded RTX Corp. (NYSE:RTX) stock from Hold to Buy, raising its price target to $220 from $210, citing expected margin expansion in the company's commercial business. The firm increased its EPS estimates for 2026-2028 by approximately 5% on average, driven by operational improvements and pricing gains. RTX is also projected to generate over $9 billion in discretionary free cash flow in the next three years and has maintained dividend payments for 56 consecutive years.

Teledyne FLIR Defense has secured an $11.2 million contract from the U.S. Army to supply over 45 advanced Chemical, Biological, Radiological, and Nuclear (CBRN) unmanned aerial system kits. These SkyRaider®-based systems will enhance battlefield protection by autonomously mapping CBRN threats, thereby safeguarding soldiers from exposure. The kits, developed under the Army's CSIRP program, integrate Teledyne FLIR's R80D SkyRaider® with modular CBRN detection payloads and are expected to begin deliveries in Q2 2026.